Connect your AI

Ultragenyx Pharmaceutical RARE Total Equity

Total Equity at other companies

Eli LillyLLY

$31.2B+97.9%

AmgenAMGN

$9.19B+48.1%

Ionis PharmaceuticalsIONS

$491.41M+3.3%

Arrowhead ResearchARWR

$613.98M-10.1%

CRISPR TherapeuticsCRSP

$1.81B-0.8%

ModernaMRNA

$7.41B-26.4%

Other financials

Income statement

Revenue$136.0M-2.2%

Operating income-$169.0M-18.2%

Net income-$185.0M-22.5%

EPS (diluted)-$1.84-17.2%

Balance sheet

Cash & equivalents$175.0M+37.8%

Total debt$36.0M-10.8%

Total assets$1.3B-1.2%

Cash flow

Operating cash flow-$197.0M-18.7%

CapEx$1.0M0.0%

Free cash flow-$198.0M-18.6%

Valuation

Market cap$2.83B-39.4%

P/S4.2×-3.7×

Profitability

Gross margin97.2%—

Operating margin-83.8%-3.0pp

Net margin-90.9%-2.1pp

FCF margin-75.1%+10.7pp

Returns & leverage

Return on equity-325.6%+36.9pp

Debt / equity3.7×—

Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Ultragenyx Pharmaceutical's total equity?: Ultragenyx Pharmaceutical (RARE) reported total equity of -$236M in Q1 2026.
How has Ultragenyx Pharmaceutical's total equity changed year-over-year?: Ultragenyx Pharmaceutical's total equity decreased by 263.9% year-over-year, from $144M to -$236M.
What is the long-term trend for Ultragenyx Pharmaceutical's total equity?: Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's total equity has grown at a -41.4% compound annual growth rate (CAGR), from $1.15B to -$80M.
What does total equity mean?: Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.